Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34402546.
- Also identified by DOI 10.1002/ana.26196 and PMC identifier 8555870.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Central nervous system demyelination in multiple sclerosis (MS) and subsequent axonal degeneration represent a major cause of clinical morbidity. Learning, salient experiences, and stimulation of neuronal activity induce new myelin formation in rodents, and in animal models of demyelination, remyelination can be enhanced via experience- and activity-dependent mechanisms. Furthermore, preliminary studies in MS patients support the use of neuromodulation and rehabilitation exercises for symptomatic improvement, suggesting that these interventions may represent nonpharmacological strategies for promoting remyelination. Here, we review the literature on myelin plasticity processes and assess the potential to leverage these mechanisms to develop remyelinating therapies. ANN NEUROL 2021;90:558-567.
Medical subject headings
- Multiple Sclerosis
- Myelin Sheath
- Neuronal Plasticity
- Remyelination